Abstract: An aerodynamic system comprising a torsion tube, a first rotatory coupling coupled to the torsion tube and adapted to mount to a first wheel hub, a second rotary coupling coupled to the torsion tube distal from the first rotary coupling and adapted to mount to a second wheel hub, and a non-rotating fairing panel mounted to the torsion tube.

Abstract: Aerodynamic wheel covers may include a hub assembly coupled with a hub of a large vehicle, such as a truck. A base assembly may be coupled to the hub assembly, and a disk assembly may be coupled with the base assembly such that removal and installation of the disk assembly may be accomplished without tools.

Abstract: A chassis mounted energy extraction and delivery system. In one embodiment, a gravity-referenced, external tire inflation facility is integrated into an aerodynamic fairing mounted on the chassis of a vehicle. In one other embodiment, a torsion bar coupled between a hub-mounted energy extraction or delivery facility and a selected portion of the chassis provides a cross-referenced fixed point of reference. In a dual-axle embodiment, a first end of the torsion bar is coupled to the hub of one axle and a second end of the torsion bar is coupled to the hub of the other axle. In a single-axle embodiment, the second end of the torsion bar is coupled to the chassis.

Abstract: The present disclosure relates to bifunctional chemical epigenetic modifiers, and methods of making, kits and using the bifunctional chemical epigenetic modifiers. The bifunctional chemical epigenetic modifiers can include a FK506 molecule or derivative thereof, a linker and a bifunctional ligand. The bifunctional ligand can be a histone deacetylase inhibitor.

Abstract: The present disclosure relates to chemical compounds that inhibit HP1-mediated heterochromatin formation, pharmaceutical compositions containing such compounds, methods of identifying such compounds, and their use in the treatment of disorders related to heterochromatin formation such as, for example, a disorder of cellular proliferation (e.g., cancer). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: The present disclosure relates to bifunctional chemical epigenetic modifiers, and methods of making, kits and using the bifunctional chemical epigenetic modifiers. The bifunctional chemical epigenetic modifiers can include a FK506 molecule or derivative thereof, a linker and a bifunctional ligand. The bifunctional ligand can be a histone deacetylase inhibitor.

Abstract: The present disclosure relates to chemical compounds that inhibit HP1-mediated heterochromatin formation, pharmaceutical compositions containing such compounds, methods of identifying such compounds, and their use in the treatment of disorders related to heterochromatin formation such as, for example, a disorder of cellular proliferation (e.g., cancer). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.